1. L3 Effects on serum bile acids, pruritus, and safety with up to 72 weeks of odevixibat treatment: pooled data from the PEDFIC 1 and PEDFIC 2 studies in children with progressive familial intrahepatic cholestasis. (12th September 2022) Authors: Loomes, Kathleen M; Verkade, Henkjan J; Thompson, Richard J; Kamath, Binita M; Hardikar, Winita; Lacaille, Florence; Mozer-Glassberg, Yael; Shteyer, Eyal; Calvo, Pier Luigi; Dalgic, Buket; Grammatikopoulos, Tassos; Rajwal, Sanjay R; Vittorio, Jennifer M; Soufi, Nisreen; McKiernan, Patrick; Tessie... Journal: Frontline gastroenterology Issue: Volume 13(2022)Supplement 1 Page Start: A47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. (September 2022) Authors: Thompson, Richard J; Arnell, Henrik; Artan, Reha; Baumann, Ulrich; Calvo, Pier Luigi; Czubkowski, Piotr; Dalgic, Buket; D'Antiga, Lorenzo; Durmaz, Özlem; Fischler, Björn; Gonzalès, Emmanuel; Grammatikopoulos, Tassos; Gupte, Girish; Hardikar, Winita; Houwen, Roderick H J; Kamath, Binita M; Karpen,... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 9(2022) Page Start: 830 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗